Hormone receptor measurements and survival in 1335 consecutive patients with primary invasive breast carcinoma

International Journal of Oncology

Volumn 12, Issue 5, 1998, Pages 1091-1096

  Raabe, Nils Kristian ^a   Hagen, Steinar ^b   Haug, Egil ^c   Fossaa, Sophie Dorothea ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast carcinoma; Estrogen receptor; Progesterone receptor; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HORMONE RECEPTOR INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031955422     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.5.1091     Document Type: Article

References (21)

1. Report from the Breast Cancer Trials Comittee, Scottish Cancer Trials Office (MRC): Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial, Edinburgh. Lancet : 171-175, 1987.
2. Aamdal S, Boermer O, Joergensen O, et al: Estrogen receptors and long-term prognosis in breast cancer. Cancer 53: 2525- 2529, 1984.
3. Raemaekers JMM, Bcex LVAM, Koenders AJM, et al: Disease-free interval and estrogen receptor activity in tumour tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat 6: 123-30, 1985.
4. Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C and Brunet M: Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1262 patients. Eur J Cancer 25: 1233-1240, 1989.
5. Alanko A, Heinonen E, Scheinin T, Tolppanen EM and Vihko R: Significance of estrogen and progesterone receptors, disease-free interval and site of first metastasis on survival of breast cancer patients. Cancer 56: 1696-1700, 1985.
6. Blanco G, Holli K, Heikkinen M, Kallioniemi OP and Taskinen P: Prognostic factors in recurrent breast cancer: Relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 62: 142-146, 1990.
7. Crowe JP, Gordon NH, Hubay CA, Shenk RR, Zollinger RM, Brumberg DJ, et al: Estrogen receptor determination and long-term survival of patients with breast carcinoma. Surg Gynecol Obstet 173: 273-278, 1991.
8. Andry G, Suciu S, Pratola D, Sylvester R, Leclercq G, Da Costa PM, et al: Relation between estrogen receptor concentration and clinical and histological factors: Their relative prognostic importance after radical mastectomy for primary breast cancer. Eur J Cancer Clin Oncol 25: 319-329, 1989.
9. Norwegian Cancer Society: Cancer mammae. Primary treatment 1st edition. Norwegian Surgical Association, Oslo, 1981.
10. Raabe NK and Fosså SD: Primary invasive breast carcinoma in Oslo 1980-89: Incidence and delay. Acta Oncol 35: 9-15, 1996.
11. Bloom HJG and Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957.
12. Godolphin W, Elwood JM and Spinelli JJ: Estrogen receptor quantification and staging as complementary prognostic indicators in breast cancer: A study of 583 patients. Int J Cancer 28: 677-683, 1981.
13. Leclercq G, Bojar H and Groussard J: Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: a European multicenter study. Cancer Res 46: 4233-4236, 1986.
14. Chamberlain J, Coleman D and Ellman R: Verification of the cause of death in the trial of early detection of breast cancer. UK Trial of Early Detection of Breast Cancer Group: Br J Cancer 64: 1151-1156, 1991.
15. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group Study. J Clin Oncol 10: 1284-1291, 1992.
16. Shek LL and Godolphin W: Survival with breast cancer: The importance of estrogen receptor quantity. Eur J Cancer Clin Oncol 25: 243-250, 1989.
17. Romain S, Laine Bidron C, Martin PM and Magdelenat H: EORTC receptor study group report. Steroid receptor distribution in 47892 breast cancers. A collaborative study of 7 European laboratories. Eur J Cancer 31 A: 411-417, 1995.
18. Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T and Keiding N: Prognostic value of steroid hormone receptors; Multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 47: 6126-6133, 1987.
19. Winstanley J, Cooke T, George WD, Murray G, Holt S, Croton R, et al: The long-term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast. Br J Cancer 64: 99-101, 1991.
20. Fisher B, Redmond C, Fisher ER and Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from national surgical adjuvant breast and bowel project protocol B-06. J Clin Oncol 6: 1076-1087, 1988.
21. Raabe NK, Kaaresen R and Fossaa SD: Analysis of adjuvant treatment in postmenopausal patients with stage II invasive breast carcinoma. A pattern of care study and quality assurance of 431 consecutive patients in Oslo 1980-1989. Acta Oncol 36: 255-260, 1997.